**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 66582

**Manuscript Type:** REVIEW

**Fully covered metal biliary stents: a review of the literature**

Lam R *et al*. Fully covered metal biliary stents

Robert Lam, Thiruvengadam Muniraj

**Robert Lam, Thiruvengadam Muniraj,** Department of Medicine, Yale University School of Medicine, New Haven, CT 06520, United States

**Author contributions:** Lam R and Muniraj T equally contributed to the work; All authors have read and approved the final manuscript.

**Corresponding author: Thiruvengadam Muniraj, FRCP, MD, PhD, Assistant Professor,** Department of Medicine, Yale University School of Medicine, 333 Cedar Street, 1080 LMP, New Haven, CT 06520, United States. thiruvengadam.muniraj@yale.edu

**Received:** March 30, 2021

**Revised:** July 9, 2021

**Accepted:** August 27, 2021

**Published online:** October 14, 2021

**Abstract**

Fully covered self-expandable metal stents (FCSEMS) represent the latest advancement of metal biliary stents used to endoscopically treat a variety of obstructive biliary pathology. A large stent diameter and synthetic covering over the tubular mesh prolong stent patency and reduce risk for tissue hyperplasia and tumor ingrowth. Additionally, FCSEMS can be easily removed. All these features address issues faced by plastic and uncovered metal stents. The purpose of this paper is to comprehensively review the application of FCSEMS in benign and malignant biliary strictures, biliary leak, and post-sphincterotomy bleeding.

**Key Words:** Fully covered self-expandable metal stents; Plastic stents; Endoscopy; Chronic pancreatitis; Biliary stricture; Biliary leak; Stent migration

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Lam R, Muniraj T. Fully covered metal biliary stents: a review of the literature. *World J Gastroenterol* 2021; 27(38): 6357-6373

**URL:** https://www.wjgnet.com/1007-9327/full/v27/i38/6357.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v27.i38.6357

**Core Tip:** Fully covered self-expandable metal stents (FCSEMS) are composed of a metal alloy tubular mesh with a synthetic covering to minimize tumor ingrowth. They have a broad range of biliary endoscopic applications, including the treatment of strictures, biliary leak, and post-sphincterotomy bleeding. Novel anchoring designs have been effective at addressing the common problem of stent migration with FCSEMS.

**INTRODUCTION**

Recent advances in endoscopic stenting have enabled the treatment of a wide range of obstructive biliary pathologies previously requiring surgical and percutaneous intervention[1]. Early randomized control studies found that endoscopic stenting compared to surgical or percutaneous intervention was associated with decreased 30 d morbidity and mortality, decreased complications rates, lower overall cost, and higher quality of life[2-4]. Plastic stents were the earliest stent type used, and metal stents were introduced later in the 1980s[5]. The purpose of this report is to review the current applications of fully covered self-expandable metal stents (FCSEMS) for biliary strictures, biliary leak, and post-sphincterotomy bleeding.

**PLASTIC STENTS**

Plastic stents are commonly used because of their efficacy, easy insertion and removal, and low cost[1,6,7] (Figure 1A). Plastic biliary stents come in various shapes and can be made of Teflon, polyethylene or polyurethane materials. Standard diameters of plastic biliary stents are 7.0 Fr, 8.5 Fr, 10.0 Fr and 11.5 Fr, and standard lengths range from 5 cm to 18 cm. Appropriate stent length is determined using a graduated guide wire and guiding catheter. Initial placement is guided using a radio-opaque guidewire. Plastic stents are equipped with side holes that allow for drainage even when the ends are impacted against the biliary or digestive tract wall, or clogged with debris. Additionally, plastic stents may have anchoring flaps to prevent stent migration. Multiple plastic stents (MPS) can be inserted during each endoscopic retrograde cholangiopancreatography (ERCP) session.

A major disadvantage of plastic stents is the tendency for occlusion due to the formation of a bacterial biofilm, leading to recurrent jaundice and pruritis[8,9]. Acute cholangitis may develop in up to 20%-40% of cases requiring the need for stent exchange[10]. Stent occlusion rates and complications of acute cholangitis are lower with large stent diameters of 10 Fr and 11.5 Fr compared to 7 Fr or 8.5 Fr stents, likely due to a higher biliary flow rate[11]. However, a retrospective study of 33 patients comparing the efficacy and complications of 10 Fr biliary stents to 11.5 Fr stents for use in malignant and benign biliary tract disease found no significant differences in success rates or complications[12]. Median patency for 10 Fr plastic stents is an estimated 4-5 mo[13]. Moreover, a special therapeutic duodenoscope with a wide working channel of 4.2 mm diameter is needed to use 11.5 Fr plastic stents.

**SELF-EXPANDABLE METAL STENTS**

Self-expandable metal stents (SEMS) were designed with a larger luminal diameter than plastic stents to prolong stent patency and address occlusion complications faced by plastic stents[14-16]. The core structure of a SEMS comprises a 4-12 cm long tubular mesh made up of metal alloys, including stainless steel, Nitinol, Elgiloy and Platinol[17] (Figure 1B). Metal alloys allow adequate radial expansible force without compromising on flexibility inside the duct. Each metal stent is more expensive than a plastic stent. However, SEMS have a lower risk of recurrent biliary obstruction compared to plastic stents. Overall, SEMS is more cost-effective than plastic stents over time, especially when life expectancy exceeds 4 mo[18-22]. Comparisons between plastic stents and different types of SEMS are summarized in Table 1.

SEMS are constrained by an 8-8.5 Fr surrounding sheath while it is inserted through a channel in the duodenoscope. Deployment occurs when the sheath is retracted, expanding the stent to a maximal diameter of 10 mm.

Mechanisms of SEMS occlusion differ from plastic stents *via* the following: (1) Tissue in-growth through the stent mesh; (2) Tumor overgrowth around the proximal or distal end of the stent; (3) Mucosal hyperplasia into the stent because of a chronic inflammatory reaction to the stent mesh; and, less commonly; and (4) Biliary sludge[23-26]. In contrast to plastic stents, occluded SEMS with tumor or tissue in-growth or over-growth are often difficult to reposition or remove once deployed[27]. Treatment of a SEMS occlusion involves insertion of new plastic stents or deployment of another SEMS within the initial stent. Mechanical cleaning with an extraction balloon may also be helpful[28]. Additional complications of SEMS include duodenal wall erosion by the stent, which may lead to duodenal perforation and acute bleeding[29].

Stent designs continue to evolve to overcome these factors. Silicone, polyurethane, and expanded polytetrafluoroethylene coverings may be applied over a part (partly-covered) or entire (fully-covered) length of SEMS to prevent tumor in-growth through the mesh[27,30] (Figures 1C, 1D, and 1E). Additionally, the covering allows for easier SEMS removal compared to bare-metal stents[31].

**BENIGN BILIARY STRICTURES**

Benign biliary strictures (BBS) form after an initial insult to the biliary duct that leads to inflammation, collagen deposition, fibrosis, and bile duct narrowing[32]. Common causes include post-operative injury, chronic pancreatitis (CP), and chronic inflammatory cholangiopathies (Table 2)[33]. BBS may present with pain, jaundice, pruritis, and/or elevated liver function tests[34]. A combination of magnetic resonance cholangiopancreatography (MRCP) and/or endoscopic (ERCP) retrograde cholangiopancreatography may be used during the evaluation process to elucidate biliary ductal anatomy[35]. Tissue sampling *via* endoluminal biopsy or biliary brushings will confirm non-malignant tissue and determine the primary etiology. ERCP is the therapeutic modality of choice for BBS because of its efficacy, safety, and noninvasive nature[36-38].

***Post-operative BBS***

The most common causes of post-operative BBS occur after cholecystectomy and biliary duct surgery[39,40]. An effective means of therapeutic decompression using plastic stents can be achieved with the placement of MPS side-by-side across the stricture[41]. Plastic stents used for up to 1 year with interval replacement in 3-4 mo intervals have demonstrated excellent safety, high clinical success rates, and low rates of stricture recurrence[42]. Plastic stent occlusion within 4-5 mo requiring endoscopic stent exchange is a major limitation because of overall cost and requirement for patient compliance[13,43].

In contrast, FCSEMS can expand to a large stent diameter equivalent to three 10 Fr stents, and its chemical covering limits tissue hyperplasia and in-growth. A single FCSEMS can remain in place for a prolonged period without the need for repeated stent exchange prior to removal[44,45].

In a retrospective study of 69 patients comparing the efficacy and safety of FCSEMS and plastic stents for postsurgical BBS, findings revealed a similar technical success rate (100% in both groups) and stricture recurrence (16% in the PS group and 22% in the FCSEMS group)[46]. However, the median duration of stenting in the FCSEMS group (5.2 mo) was significantly lower than that of the PS group (10.7 mo), requiring multiple stent exchanges. In fact, the FCSEMS group had a shorter total operation and fluoroscopy time because only one metal stent needed to be deployed compared to 2-5 plastic stents in the PS group. The study highlighted the use of FCSEMS as a practical and effective alternative means to the endoscopic treatment of post-surgical BBS with plastic stents.

A prospective, nonrandomized study of 18 patients also evaluated the 6-12 mo temporary use of FCSEMS for symptomatic post-cholecystectomy BBS, including a 5 year follow-up time period[47]. Successful FCSEMS placement deployment and removal was achieved in 83% of patients with a median indwell time of 11 mo. As well, 72% of patients achieved stricture resolution at the end of the FCSEMS indwell period. Kaplan Meier analysis predicted 61% probability of remaining stent-free among patients who received FCSEMS. Complications included spontaneous stent migration (17%) and stent-related adverse events, including cholangitis (33%) and pancreatitis (6%). Despite a large sample size and absence of a control group, the study showcased that temporary 1-year placement of FCSEMS can maintain long-term stricture resolution. Table 3 highlights differences in study outcomes between plastic stents and FCSEMS for use in post-operative BBS.

***Anastomotic biliary strictures from orthostatic liver transplantation***

Anastomotic biliary strictures (AS) are responsible for nearly 80% of biliary strictures after orthostatic liver transplantation (OLT)[48,49]. They typically occur within 1-2 mo of surgery, and are characterized as single BBS short in length. Existing strategies to treat AS associated BBS include balloon dilatation and endoscopic stenting[50]. While the use of MPS is the gold standard similar to the treatment post-cholecystectomy BBS, premature stent occlusion is a major limitation[51-53].

In the only meta-analysis to date comparing FCSEMS to plastic stents in the use of post-OLT AS, there was no significant difference in stricture resolution, complications, and recurrence[54]. However, FCSEMS use was associated with reduced treatment time (mean difference of -3.58 mo). Complications of pancreatitis and post-procedural pain were more common in FCSEMS. While prior studies have identified FCSEMS with stent migration rates as high as 33%, this adverse event could not be compared in the metanalysis because it was inconsistently reported across the 7 included studies[55,56].

Novel FCSEMS designs with antimigration properties have been developed to address shortcomings with stent migration. A retrospective multicenter Australian study evaluated the use of a novel FCSEMS in 36 patients for treatment of AS after OLT. Some of the patients within the cohort had failed the MPS approach[57]. The Niti-S FCSEMS biliary stent (Taewoong Medical Co Ltd., South Korea) used had an antimigration waist, short stent length, and a removable string for easy removal. Average duration of indwell treatment time was 3.8 mo. Stricture resolution was achieved in 100% of patients and all stents were removed without any difficulty. Only 2.8% of patients experienced stent migration. Nearly 75% of patients remained free of AS recurrence. Excellent clinical and technical success in this study with low rates of stent migration was a major breakthrough in the use of FCSEMS with anti-migration features for AS.

A more recent British retrospective study also evaluated the same type of antimigration FCSEMS (Taewoong Medical Co Ltd., South Korea) in a cohort of 62 patients[58]. Approximately 96% of patients had immediate stricture resolution after 12 wk indwell time. Furthermore, 72% of patients continued to maintain long-term resolution of the AS with a mean follow up period of 548 d. No stent migration occurred in any of the patients. Complication rates were low at 15%, and were primarily stent and procedure-related, such as pancreatitis, cholangitis and wire-guided perforation.

Overall, study findings using FCSEMS with new antimigration designs have shown promise in their application for post-OLT AS treatment. Larger cohort and randomized controlled studies should compare these novel FCSEMS to plastic stents. Alternative antimigration designs should be considered to maximize safe indwell time of stents.

***CP***

CP-associated BBS are a consequence of recurrent inflammation and subsequent fibrosis. Stricture formation occurs in up to 30% to 40% of cases[59]. Endoscopic intervention is focused on draining the main pancreatic duct to provide pancreatic decompression[60]. Historically, the strictures were treated *via* balloon dilation and endoscopic plastic stent placement, requiring up to 3 or more ERCP sessions[61]. Current recommendations from the Asia-Pacific guidelines recommend the use of FCSEMS or MPS for the endoscopic treatment of CP-associated BBS[62]. To date, the WallFlex Biliary RX Fully Covered Stent (Boston Scientific, United States) is the only FCSEMS approved by the United States Food and Drug Administration for treatment of BBS due to CP for indwell time up to 12 mo[63].

Existing retrospective and case series studies have supported the use of FCSEMS for the treatment of refractory pancreatic duct strictures: clinical and technical success rates have been as high as 90%-100% with a shorter indwell time compared to plastic stents[64-66]. The largest and longest prospective study to date investigated long-term outcomes after 10-12 mo indwell of a single FCSEMS for CP-associated BBS[67]. The cohort consisted of 118 patients, most of whom had failed previous treated with plastic stents. Patients were regularly followed for 5 years after FCSEMS removal. Approximately 80% of patients had stricture resolution at the time of stent removal. Nearly 62% of patients remained stent-free following 75 mo of FCSEMS placement. The success rate was relatively high compared to traditional outcomes with a single plastic stent, which faces issues of short occlusion time[68,69]. In fact, 78% of patients who had a resolved BBS post-indwell continued to remain stent free for 5 years. Of note, 23% of patients experienced serious adverse events that were mostly stent-related, including cholangitis, pancreatitis, and cholecystitis. This study was important in further demonstrating the single-use application of FCSEMS for CP BBS with long term stricture-free durability. This is notable in CP BBS, which notoriously has a poor response to endoscopic intervention with high risks of recurrence.

**MALIGNANT BILIARY STRICTURES**

Malignant biliary strictures (MBS) are most commonly caused by pancreatic cancer, but can also be caused by cholangiocarcinoma and metastatic disease[70,71]. Clinical presentation is consistent with biliary duct obstruction, including jaundice and cholestatic pattern of transaminase elevation. While MBS shares the same diagnostic evaluation as BBS with MRCP and/or ERCP modalities, tissue sampling will be the differentiating factor with findings of malignancy. Prognosis is poor 5-year survival rates for pancreatic cancer and cholangiocarcinoma are 8% and 10% respectively[72,73].

***Non-hilar MBS***

Among the 30% of MBS cases which are surgically resectable, endoscopic intervention may be considered to provide preoperative biliary decompression (PBD) (Figures 2A and 2B). PBD decompression is an area of great controversy because of the risks for serious complications, including pancreatitis and cholangitis. A landmark randomized control trial of 202 patients with a pancreatic head cancer compared the outcomes of preoperative biliary drainage for 5 wk to 6 wk preceding surgery to surgery alone. The biliary drainage group had significantly higher (74%) rates of complications than the surgery alone group (39%). Mortality or hospital length of stay did not differ between both groups[74]. Metanalyses investigating the benefits of preoperative biliary drainage has found similar results–length of hospital stay and mortality rate are comparable in preoperative biliary drainage and surgery alone groups[75,76]. Currently, preoperative biliary drainage is indicated for patients with MBS with concurrent severe symptomology (*i.e*., severe pruritis, cholangitis), elevated bilirubin > 250 μmol/L, or patients undergoing neoadjuvant chemotherapy[77,78].

Nearly 70% of MBS are surgically unresectable at the initial presentation[79]. Endoscopic palliative stent placement for symptom relief is one approach to management. SEMS placement is preferred over plastic stents, especially when life expectancy is greater than 4-6 mo – SEMS have lower rates of stent dysfunction, reintervention, and cholangitis, and higher survival and stent patency rates[80-82].

Outcomes of FCSEMS compared to uncovered self-expandable metal stents (USEMS) in patients with unresectable MBS have also been extensively studied. A randomized controlled trial (RCT) of 749 patients with MBS investigated the outcomes of FCSMES *vs* USEMS placement. No significant difference was found between both groups for patency or survival rates[83]. Tumor ingrowth was higher in the USEMS group compared to the FCSEMS group. However, patients in the FCSEMS were more prone to stent migration and acute pancreatitis. Another recent RCT compared the use of FCSEMS to USEMS in 158 patients with nonresectable MBS. Surprisingly, median stent patency was lower for the FCSEMS (240 d) than the USEMS (541 d) group[84]. Consistent with the other study, FCSEMS had a significantly higher rate of migration, with no difference in overall survival between both groups[84]. To explain the stent patency finding in the FCSEMS group, the study proposed that occlusion may not be due to tumor ingrowth per se. The specific NitiS FCSEMS stent chosen for the study may promote an inflammatory reaction causing tissue hyperplasia. Thus, this finding may not be generalizable to all FCSEMS.

Metanalyses have also investigated this topic with mixed results, including studies with partly covered SEMS. A metanalysis involving 5 RCTs with 781 patients showed that CSEMS had superior patency rates compared with UCSEMS for MBS[85]. However, another metanalysis involving 9 RCTs with 1061 patients found no difference in stent patency between both groups[86].

Overall, there is no consensus regarding the superiority of FCSEMS or USEMS for palliative decompression of MBS. FCSEMS may be preferred for ease of removal or in circumstances where tumor ingrowth risk is high, such as in pancreatic cancer or cholangiocarcinoma. However, the problem of stent migration should be factored into the management decision. UCSEMS should be considered when there is short survival time or where likelihood of tumor in growth is low.

***Hilar MBS***

Malignant Hilar Strictures (MHS) are most commonly unresectable at presentation[87] (Figure 2C). MHS are classified by the Bismuth-Corlette classification, which accounts for the extent of involvement of the hilum and/or left or right main hepatic ducts[88]. The goal of management is to provide palliative decompression to improve quality of life, reduce jaundice, and decrease risk of cholangitis[89]. As with other MBS, metal stents are preferred over plastic ones because of superior patient survival, drainage rate, and stent patency[90]. Stent placement in the hilar region is technically difficult, and can be managed by unilateral or bilateral stenting (Figures 2D and 2E). Bilateral stenting can be approached *via* stent in stent or side by side approach[91].

A RCT involving 159 patients with malignant hilar biliary obstruction showed that patients with unilateral stenting (88.6%) had significantly higher rate of technical success than bilateral stenting (76.9%)[92]. Additionally, the bilateral stent group (16.6%) had significantly higher rates of early cholangitis. Study findings suggested that unilateral drainage was superior to bilateral stenting with lower risk of adverse complications. However, a more recent multicenter RCT found no significant difference in the technical success rate between bilateral (95.5%) and unilateral groups (100%). The median stent patency was higher in the bilateral group (252 d) than the unilateral (139 d), with fewer reinterventions needed for the bilateral group[93]. A metanalysis with 1292 patients found higher success rate in the unilateral group (97%) than the bilateral group (89%)[94]. Other retrospective studies have found comparable rates of technical success between both groups[95-98]. Overall, there is no clear consensus whether the unilateral or bilateral approach is superior. Unilateral approach may be preferred given the technical difficulty of bilateral placement.

Y-shaped bilateral SEMS devices have also been designed, which offers an effective and safe approach for unresectable MHS[98,99]. However, they are yet to be practiced routinely across endoscopic centers.

**BILIARY LEAK**

Biliary leak occurs due to traumatic injury or iatrogenic injury to the biliary duct from cholecystectomy, ERCP, liver resection, or orthostatic liver transplantation[100-103]. Biliary leak tends to present within 1 wk postoperatively, and are commonly located at the end of the cystic duct stump or duct of Luschka[104]. Minor bile duct leaks are characterized by low drain output and self-resolve without intervention[105]. In contrast, complex bile leaks are characterized by the persistent biliary discharge from an open T-tube or drain[106,107]. Standard of care involves plastic stent placement with or without sphincterotomy to reduce transpapillary pressure gradient[108]. As a result, bile drainage will preferentially drain into the duodenum and bypass the site of bile leak. Complex bile leaks commonly occur in anastomotic bile leaks following orthostatic liver transplantation or cholecystectomy, and may be refractory to plastic stent intervention[103,109]. FCSEMS have been investigated for use in these situations because of the larger expansile diameter and membrane coating, which theoretically provides an effective seal at the site of the leak (Figures 3A and 3B).

In a retrospective study investigating patients with complex post-OLT bile leaks treated with CSEMS placement, successful deployment and long-term leakage control was achieved using FCSEMS with fins (77.8% of patients) and FCSEMS with flared ends (70%)[110]. A concerning finding was that large number of patients who received FCSEMS with fins (35%) experienced post-stent removal biliary strictures. This likely occurred due to stent-induced biliary duct compression and ischemia, which highlights one of the major risks of FCSEMS use for biliary leak.

Another US-based study evaluated the use of Viabil FCSEMS (Gore, United States) placement for 5 patients with bile leaks[111]. All patients had successfully sealed bile leaks confirmed with cholangiogram. Most patients did not have any complications. However, 1 patient developed a hepatic abscess and sepsis. Another patient had stent occlusion after being lost to followup for 8.5 mo, but post-ERCP removal of the occluded stent revealed a sealed bile leak on cholangiogram.

A pilot study consisted of 16 patients who underwent CSEMS placement for a biliary leak. These patients either failed to respond to conventional ERCP or had severe comorbidities that prevented multiple procedures[112]. Nearly all (15/16 patients) of the patients had complete resolution of the leak confirmed with cholangiogram. Only 1 proximal and distal migration complication was documented.

In summary, existing studies have demonstrated proof of successful bile leak closure using FCSEMS (Table 4). However, complications, including stent migration and post-removal strictures, make the widespread use of FCSEMS for complex biliary leaks debatable. Future studies should investigate this topic using larger cohort sizes.

**POST-SPHINCTEROTOMY BLEEDING**

Biliary endoscopic sphincterotomy (ES) refers to the resection of the biliary sphincter and intraduodenal segment of the common bile duct. It is an essential procedure for ERCP in the treatment for a variety of biliary and papillary disease, including choledocholithiasis, bile leak, and biliary strictures[113]. Post-endoscopic bleeding is a major complication of biliary sphincterotomy[114]. Most post-ES bleeds are small and resolve spontaneously[115]. Other cases present with significant bleeding requiring blood transfusion support and urgent endoscopic intervention. While existing methods include injection, balloon tamponade, and mechanical (*e.g*., embolization) approaches, endoscopic hemostasis can also be achieved by tamponade effect *via* FCSEMS deployment[113].

The largest retrospective study to date evaluated 67 patients with post-ES bleeding, and compared the use of FCSEMS treatment *vs* non-FCSEMS treatment (*e.g*., balloon tamponade, sclerotherapy, epinephrine injection, thermal cautery or clip placement)[116]. At 72 h post intervention, the study found that the FCSEMS group (0.66 g/dL) had a significantly lower bleeding rate than the non-FCSEMS group (1.98 g/dL) even though the proportion of patients determined to be at high risk for post-ES bleeding was higher in the FCSEMS treatment group (40%) *vs* non-FCSEMS treatment group (9%). All patients in the FCSEMS group achieved hemostasis, and no adverse events were documented. The study findings supported the use of FCSEMS in patients with severe or immediate bleeding not responsive to initial endoscopic treatment.

Smaller-sized retrospective and case studies have demonstrated similar success with complete hemostasis using FCSEMS for difficult-control post-ES bleeding[117,118]. No studies to date have investigated the use of FCSEMS as primary post-ES treatment therapy. Larger perspective and randomized controlled studies should be conducted to evaluate the optimal timing for FCSEMS removal after achieving hemostasis.

**COMPLICATIONS**

Stent migration is the most frequent complication of FCSEMS, which occurs in 20%-40% of cases[119,120]. Proximal stent migration refers to FCSEMS migration into the biliary duct, while distal stent migration refers to migration to the duodenum or bowel. Endoscopic intervention is needed to remove and replace the displaced stent. A prospective study comparing the temporary use of FCSEMS with unflared ends to flared ends in patients with CP-related BBS revealed the migration rate was 100% for unflared FCSEMS compared to 40% of flared FCSEMS[121]. FCSEMS designed with anchoring flaps or flared ends are preferred as they reduce the risk of migration. A multicenter, prospective study of compared the antimigration effects and efficacy of FCSEMS with an anchoring flap to a flared end at the proximal end. After a median followup time of 6 mo, none of the patients in the anchoring flap had stent migration compared to 33% of patients in the flared end, suggesting that the anchoring flap design was superior to the flared end design. Both types of FCSEMS were able to be removed in all of the patients[122]. Overall, new stent designs including anchoring flaps, flared ends, and additional anchoring plastic stents have been validated in studies to reduce migration risk[123-125].

Cholecystitis is another complication associated with FCSEMS use most commonly in MBS. The pathophysiological mechanism is thought to be obstruction of biliary flow if the cystic duct orifice is obstructed by the synthetic covering of the FCSEMS[126,127].

Stent occlusion may occur from tumor ingrowth, tissue overgrowth, or sludge, predisposing to the development of cholangitis[23-26]. However, time to and rate of occlusion is considerably less compared to plastic stents[128]. Factors such as FCSEMS location and treatment indication dictate different levels of risk[129].

**CONCLUSION**

FCSEMS represents the latest development of SEMS used by endoscopists treat a variety of benign and malignant biliary pathology, including biliary leak, post-sphincterotomy bleeding, and strictures. A chemical covering reduces the risk of tissue hyperplasia and tumor ingrowth, prolonging stent patency. The studies examined in our review have shown that FCSEMS can be clinically effective for a variety of endoscopic applications. However, FCSEMS commonly face problems of stent migration, which can be addressed with modifications including flared ends and anchoring flaps. Future areas of research will continue to expand the interventional applications using FCSEMS, and design new modifications to reduce complications.

**REFERENCES**

1 **Mangiavillano B**, Pagano N, Baron TH, Arena M, Iabichino G, Consolo P, Opocher E, Luigiano C. Biliary and pancreatic stenting: Devices and insertion techniques in therapeutic endoscopic retrograde cholangiopancreatography and endoscopic ultrasonography. *World J Gastrointest Endosc* 2016; **8**: 143-156 [PMID: 26862364 DOI: 10.4253/wjge.v8.i3.143]

2 **Brandabur JJ**, Kozarek RA, Ball TJ, Hofer BO, Ryan JA Jr, Traverso LW, Freeny PC, Lewis GP. Nonoperative versus operative treatment of obstructive jaundice in pancreatic cancer: cost and survival analysis. *Am J Gastroenterol* 1988; **83**: 1132-1139 [PMID: 2458678]

3 **Raikar GV**, Melin MM, Ress A, Lettieri SZ, Poterucha JJ, Nagorney DM, Donohue JH. Cost-effective analysis of surgical palliation versus endoscopic stenting in the management of unresectable pancreatic cancer. *Ann Surg Oncol* 1996; **3**: 470-475 [PMID: 8876889 DOI: 10.1007/bf02305765]

4 **Luman W**, Cull A, Palmer KR. Quality of life in patients stented for malignant biliary obstructions. *Eur J Gastroenterol Hepatol* 1997; **9**: 481-484 [PMID: 9187881 DOI: 10.1097/00042737-199705000-00013]

5 **Obuch JC**, Wagh MS. Endoscopic therapy for benign biliary strictures: evaluation of metal *vs.* plastic biliary stents. *Hepatobiliary Surg Nutr* 2017; **6**: 268-271 [PMID: 28848751 DOI: 10.21037/hbsn.2017.05.04]

6 **Yeoh KG**, Zimmerman MJ, Cunningham JT, Cotton PB. Comparative costs of metal versus plastic biliary stent strategies for malignant obstructive jaundice by decision analysis. *Gastrointest Endosc* 1999; **49**: 466-471 [PMID: 10202060 DOI: 10.1016/s0016-5107(99)70044-1]

7 **ASGE Technology Assessment Committee**, Pfau PR, Pleskow DK, Banerjee S, Barth BA, Bhat YM, Desilets DJ, Gottlieb KT, Maple JT, Siddiqui UD, Tokar JL, Wang A, Song LM, Rodriguez SA. Pancreatic and biliary stents. *Gastrointest Endosc* 2013; **77**: 319-327 [PMID: 23410693 DOI: 10.1016/j.gie.2012.09.026]

8 **Vaishnavi C**, Samanta J, Kochhar R. Characterization of biofilms in biliary stents and potential factors involved in occlusion. *World J Gastroenterol* 2018; **24**: 112-123 [PMID: 29358888 DOI: 10.3748/wjg.v24.i1.112]

9 **Sung JJ**. Bacterial biofilm and clogging of biliary stents. *J Ind Microbiol* 1995; **15**: 152-155 [PMID: 8519471 DOI: 10.1007/BF01569819]

10 **Lee TH**, Lee SJ, Moon JH, Park SH. Technical tips and issues of biliary stenting, focusing on malignant hilar obstruction. *Minerva Gastroenterol Dietol* 2014; **60**: 135-149 [PMID: 24780948]

11 **Speer AG**, Cotton PB, MacRae KD. Endoscopic management of malignant biliary obstruction: stents of 10 French gauge are preferable to stents of 8 French gauge. *Gastrointest Endosc* 1988; **34**: 412-417 [PMID: 2460394 DOI: 10.1016/s0016-5107(88)71407-8]

12 **Kadakia SC**, Starnes E. Comparison of 10 French gauge stent with 11.5 French gauge stent in patients with biliary tract diseases. *Gastrointest Endosc* 1992; **38**: 454-459 [PMID: 1511821 DOI: 10.1016/s0016-5107(92)70476-3]

13 **Donelli G**, Guaglianone E, Di Rosa R, Fiocca F, Basoli A. Plastic biliary stent occlusion: factors involved and possible preventive approaches. *Clin Med Res* 2007; **5**: 53-60 [PMID: 17456835 DOI: 10.3121/cmr.2007.683]

14 **Huibregtse K**, Cheng J, Coene PP, Fockens P, Tytgat GN. Endoscopic placement of expandable metal stents for biliary strictures--a preliminary report on experience with 33 patients. *Endoscopy* 1989; **21**: 280-282 [PMID: 2482170 DOI: 10.1055/s-2007-1012969]

15 **Neuhaus H**, Hagenmüller F, Classen M. Self-expanding biliary stents: preliminary clinical experience. *Endoscopy* 1989; **21**: 225-228 [PMID: 2792016 DOI: 10.1055/s-2007-1012954]

16 **Irving JD**, Adam A, Dick R, Dondelinger RF, Lunderquist A, Roche A. Gianturco expandable metallic biliary stents: results of a European clinical trial. *Radiology* 1989; **172**: 321-326 [PMID: 2664861 DOI: 10.1148/radiology.172.2.2664861]

17 **Chun HJ**, Kim ES, Hyun JJ, Kwon YD, Keum B, Kim CD. Gastrointestinal and biliary stents. *J Gastroenterol Hepatol* 2010; **25**: 234-243 [PMID: 20136988 DOI: 10.1111/j.1440-1746.2009.06152.x]

18 **Davids PH**, Groen AK, Rauws EA, Tytgat GN, Huibregtse K. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. *Lancet* 1992; **340**: 1488-1492 [PMID: 1281903 DOI: 10.1016/0140-6736(92)92752-2]

19 **Knyrim K**, Wagner HJ, Pausch J, Vakil N. A prospective, randomized, controlled trial of metal stents for malignant obstruction of the common bile duct. *Endoscopy* 1993; **25**: 207-212 [PMID: 8519239 DOI: 10.1055/s-2007-1010294]

20 **Kaassis M**, Boyer J, Dumas R, Ponchon T, Coumaros D, Delcenserie R, Canard JM, Fritsch J, Rey JF, Burtin P. Plastic or metal stents for malignant stricture of the common bile duct? Results of a randomized prospective study. *Gastrointest Endosc* 2003; **57**: 178-182 [PMID: 12556780 DOI: 10.1067/mge.2003.66]

21 **Prat F**, Chapat O, Ducot B, Ponchon T, Pelletier G, Fritsch J, Choury AD, Buffet C. A randomized trial of endoscopic drainage methods for inoperable malignant strictures of the common bile duct. *Gastrointest Endosc* 1998; **47**: 1-7 [PMID: 9468416 DOI: 10.1016/s0016-5107(98)70291-3]

22 **Wagner HJ**, Knyrim K, Vakil N, Klose KJ. Plastic endoprostheses versus metal stents in the palliative treatment of malignant hilar biliary obstruction. A prospective and randomized trial. *Endoscopy* 1993; **25**: 213-218 [PMID: 7686100 DOI: 10.1055/s-2007-1010295]

23 **Lee MJ**, Dawson SL, Mueller PR, Krebs TL, Saini S, Hahn PF. Palliation of malignant bile duct obstruction with metallic biliary endoprostheses: technique, results, and complications. *J Vasc Interv Radiol* 1992; **3**: 665-671 [PMID: 1280177 DOI: 10.1016/s1051-0443(92)72920-0]

24 **Hausegger KA**, Kleinert R, Lammer J, Klein GE, Flückiger F. Malignant biliary obstruction: histologic findings after treatment with self-expandable stents. *Radiology* 1992; **185**: 461-464 [PMID: 1410354 DOI: 10.1148/radiology.185.2.1410354]

25 **Silvis SE**, Sievert CE Jr, Vennes JA, Abeyta BK, Brennecke LH. Comparison of covered versus uncovered wire mesh stents in the canine biliary tract. *Gastrointest Endosc* 1994; **40**: 17-21 [PMID: 8163131 DOI: 10.1016/s0016-5107(94)70004-4]

26 **Levy MJ**, Baron TH, Gostout CJ, Petersen BT, Farnell MB. Palliation of malignant extrahepatic biliary obstruction with plastic versus expandable metal stents: An evidence-based approach. *Clin Gastroenterol Hepatol* 2004; **2**: 273-285 [PMID: 15067620 DOI: 10.1016/s1542-3565(04)00055-2]

27 **Nam HS**, Kang DH. Current Status of Biliary Metal Stents. *Clin Endosc* 2016; **49**: 124-130 [PMID: 26911896 DOI: 10.5946/ce.2016.023]

28 **Tham TC**, Carr-Locke DL, Vandervoort J, Wong RC, Lichtenstein DR, Van Dam J, Ruymann F, Chow S, Bosco JJ, Qaseem T, Howell D, Pleskow D, Vannerman W, Libby ED. Management of occluded biliary Wallstents. *Gut* 1998; **42**: 703-707 [PMID: 9659168 DOI: 10.1136/gut.42.5.703]

29 **Miller G**, Yim D, Macari M, Harris M, Shamamian P. Retroperitoneal perforation of the duodenum from biliary stent erosion. *Curr Surg* 2005; **62**: 512-515 [PMID: 16125609 DOI: 10.1016/j.cursur.2005.03.011]

30 **Seo DW**, Sherman S, Dua KS, Slivka A, Roy A, Costamagna G, Deviere J, Peetermans J, Rousseau M, Nakai Y, Isayama H, Kozarek R; Biliary SEMS During Neoadjuvant Therapy Study Group. Covered and uncovered biliary metal stents provide similar relief of biliary obstruction during neoadjuvant therapy in pancreatic cancer: a randomized trial. *Gastrointest Endosc* 2019; **90**: 602-612.e4 [PMID: 31276674 DOI: 10.1016/j.gie.2019.06.032]

31 **Familiari P**, Bulajic M, Mutignani M, Lee LS, Spera G, Spada C, Tringali A, Costamagna G. Endoscopic removal of malfunctioning biliary self-expandable metallic stents. *Gastrointest Endosc* 2005; **62**: 903-910 [PMID: 16301035 DOI: 10.1016/j.gie.2005.08.051]

32 **Shimada H**, Endo I, Shimada K, Matsuyama R, Kobayashi N, Kubota K. The current diagnosis and treatment of benign biliary stricture. *Surg Today* 2012; **42**: 1143-1153 [PMID: 23001533 DOI: 10.1007/s00595-012-0333-3]

33 **Ma MX**, Jayasekeran V, Chong AK. Benign biliary strictures: prevalence, impact, and management strategies. *Clin Exp Gastroenterol* 2019; **12**: 83-92 [PMID: 30858721 DOI: 10.2147/CEG.S165016]

34 **Costamagna G**, Boškoski I. Current treatment of benign biliary strictures. *Ann Gastroenterol* 2013; **26**: 37-40 [PMID: 24714594]

35 **Shanbhogue AK**, Tirumani SH, Prasad SR, Fasih N, McInnes M. Benign biliary strictures: a current comprehensive clinical and imaging review. *AJR Am J Roentgenol* 2011; **197**: W295-W306 [PMID: 21785056 DOI: 10.2214/AJR.10.6002]

36 **Kahaleh M**, Brijbassie A, Sethi A, Degaetani M, Poneros JM, Loren DE, Kowalski TE, Sejpal DV, Patel S, Rosenkranz L, McNamara KN, Raijman I, Talreja JP, Gaidhane M, Sauer BG, Stevens PD. Multicenter trial evaluating the use of covered self-expanding metal stents in benign biliary strictures: time to revisit our therapeutic options? *J Clin Gastroenterol* 2013; **47**: 695-699 [PMID: 23442836 DOI: 10.1097/MCG.0b013e31827fd311]

37 **Wagh MS**, Chavalitdhamrong D, Moezardalan K, Chauhan SS, Gupte AR, Nosler MJ, Forsmark CE, Draganov PV. Effectiveness and safety of endoscopic treatment of benign biliary strictures using a new fully covered self expandable metal stent. *Diagn Ther Endosc* 2013; **2013**: 183513 [PMID: 23956613 DOI: 10.1155/2013/183513]

38 **Cahen DL**, Rauws EA, Gouma DJ, Fockens P, Bruno MJ. Removable fully covered self-expandable metal stents in the treatment of common bile duct strictures due to chronic pancreatitis: a case series. *Endoscopy* 2008; **40**: 697-700 [PMID: 18704837 DOI: 10.1055/s-2008-1077353]

39 **Machado NO**. Biliary complications postlaparoscopic cholecystectomy: mechanism, preventive measures, and approach to management: a review. *Diagn Ther Endosc* 2011; **2011**: 967017 [PMID: 21822368 DOI: 10.1155/2011/967017]

40 **Lillemoe KD**, Melton GB, Cameron JL, Pitt HA, Campbell KA, Talamini MA, Sauter PA, Coleman J, Yeo CJ. Postoperative bile duct strictures: management and outcome in the 1990s. *Ann Surg* 2000; **232**: 430-441 [PMID: 10973393 DOI: 10.1097/00000658-200009000-00015]

41 **Costamagna G**, Tringali A, Perri V, Familiari P, Boškoski I, Barbaro F, Landi R. Endotherapy of postcholecystectomy biliary strictures with multiple plastic stents: long-term results in a large cohort of patients. *Gastrointest Endosc* 2020; **91**: 81-89 [PMID: 31175873 DOI: 10.1016/j.gie.2019.05.042]

42 **Bergman JJ**, Burgemeister L, Bruno MJ, Rauws EA, Gouma DJ, Tytgat GN, Huibregtse K. Long-term follow-up after biliary stent placement for postoperative bile duct stenosis. *Gastrointest Endosc* 2001; **54**: 154-161 [PMID: 11474383 DOI: 10.1067/mge.2001.116455]

43 **Costamagna G**, Tringali A, Mutignani M, Perri V, Spada C, Pandolfi M, Galasso D. Endotherapy of postoperative biliary strictures with multiple stents: results after more than 10 years of follow-up. *Gastrointest Endosc* 2010; **72**: 551-557 [PMID: 20630514 DOI: 10.1016/j.gie.2010.04.052]

44 **Chaput U**, Vienne A, Audureau E, Bauret P, Bichard P, Coumaros D, Napoléon B, Ponchon T, Duchmann JC, Laugier R, Lamouliatte H, Védrenne B, Gaudric M, Chaussade S, Robin F, Leblanc S, Prat F. Temporary placement of fully covered self-expandable metal stents for the treatment of benign biliary strictures. *United European Gastroenterol J* 2016; **4**: 403-412 [PMID: 27403307 DOI: 10.1177/2050640615606550]

45 **García-Cano J**. Use of fully covered self-expanding metal stents in benign biliary diseases. *World J Gastrointest Endosc* 2012; **4**: 142-147 [PMID: 22523615 DOI: 10.4253/wjge.v4.i4.142]

46 **Wu J**, Zhou DX, Wang TT, Gao DJ, Hu B. A New Fully Covered Self-Expandable Metal Stent for the Treatment of Postsurgical Benign Biliary Strictures. *Dig Dis Sci* 2017; **62**: 2550-2557 [PMID: 28776138 DOI: 10.1007/s10620-017-4698-4]

47 **Tringali A**, Reddy DN, Ponchon T, Neuhaus H, Lladó FG, Navarrete C, Bruno MJ, Kortan PP, Lakhtakia S, Peetermans J, Rousseau M, Carr-Locke D, Devière J, Costamagna G; Benign Biliary Stenoses Working Group. Treatment of post-cholecystectomy biliary strictures with fully-covered self-expanding metal stents - results after 5 years of follow-up. *BMC Gastroenterol* 2019; **19**: 214 [PMID: 31830897 DOI: 10.1186/s12876-019-1129-3]

48 **Balderramo D**, Navasa M, Cardenas A. Current management of biliary complications after liver transplantation: emphasis on endoscopic therapy. *Gastroenterol Hepatol* 2011; **34**: 107-115 [PMID: 20692731 DOI: 10.1016/j.gastrohep.2010.05.008]

49 **Villa NA**, Harrison ME. Management of Biliary Strictures After Liver Transplantation. *Gastroenterol Hepatol (N Y)* 2015; **11**: 316-328 [PMID: 27482175]

50 **Ryu CH**, Lee SK. Biliary strictures after liver transplantation. *Gut Liver* 2011; **5**: 133-142 [PMID: 21814591 DOI: 10.5009/gnl.2011.5.2.133]

51 **Tabibian JH**, Asham EH, Han S, Saab S, Tong MJ, Goldstein L, Busuttil RW, Durazo FA. Endoscopic treatment of postorthotopic liver transplantation anastomotic biliary strictures with maximal stent therapy (with video). *Gastrointest Endosc* 2010; **71**: 505-512 [PMID: 20189508 DOI: 10.1016/j.gie.2009.10.023]

52 **Rerknimitr R**, Sherman S, Fogel EL, Kalayci C, Lumeng L, Chalasani N, Kwo P, Lehman GA. Biliary tract complications after orthotopic liver transplantation with choledochocholedochostomy anastomosis: endoscopic findings and results of therapy. *Gastrointest Endosc* 2002; **55**: 224-231 [PMID: 11818927 DOI: 10.1067/mge.2002.120813]

53 **Holt AP**, Thorburn D, Mirza D, Gunson B, Wong T, Haydon G. A prospective study of standardized nonsurgical therapy in the management of biliary anastomotic strictures complicating liver transplantation. *Transplantation* 2007; **84**: 857-863 [PMID: 17984838 DOI: 10.1097/01.tp.0000282805.33658.ce]

54 **Facciorusso A**, Rosca EC, Ashimi A, Ugoeze KC, Pathak U, Infante V, Muscatiello N. Management of anastomotic biliary stricture after liver transplantation: metal versus plastic stent. *Ann Gastroenterol* 2018; **31**: 728-734 [PMID: 30386124 DOI: 10.20524/aog.2018.0297]

55 **Tarantino I**, Mangiavillano B, Di Mitri R, Barresi L, Mocciaro F, Granata A, Masci E, Curcio G, Di Pisa M, Marino A, Traina M. Fully covered self-expandable metallic stents in benign biliary strictures: a multicenter study on efficacy and safety. *Endoscopy* 2012; **44**: 923-927 [PMID: 22893134 DOI: 10.1055/s-0032-1310011]

56 **Cantù P**, Tarantino I, Baldan A, Mutignani M, Tringali A, Lombardi G, Cerofolini A, Di Sario A, Catalano G, Bertani H, Ghinolfi D, Boarino V, Masci E, Bulajic M, Pisani A, Fantin A, Ligresti D, Barresi L, Traina M, Ravelli P, Forti E, Barbaro F, Costamagna G, Rodella L, Maroni L, Salizzoni M, Conigliaro R, Filipponi F, Merighi A, Staiano T, Monteleone M, Mazzaferro V, Zucchi E, Zilli M, Nadal E, Rosa R, Santi G, Parzanese I, De Carlis L, Donato MF, Lampertico P, Maggi U, Caccamo L, Rossi G, Vecchi M, Penagini R. Endo-therapies for biliary duct-to-duct anastomotic stricture after liver transplantation: Outcomes of a nationwide survey. *Liver Int* 2019; **39**: 1355-1362 [PMID: 30500104 DOI: 10.1111/liv.14010]

57 **Aepli P**, St John A, Gupta S, Hourigan LF, Vaughan R, Efthymiou M, Kaffes A. Success and complications of an intra-ductal fully covered self-expanding metal stent (ID-FCSEMS) to treat anastomotic biliary strictures (AS) after orthotopic liver transplantation (OLT). *Surg Endosc* 2017; **31**: 1558-1563 [PMID: 27572066 DOI: 10.1007/s00464-016-5138-9]

58 **Warner B**, Harrison P, Farman M, Devlin J, Reffitt D, El-Sherif Y, Khorsandi SE, Prachalias A, Cerisuelo MC, Menon K, Jassem W, Srinivasan P, Vilca-Melendez H, Heneghan M, Heaton N, Joshi D. A unique type of fully covered metal stent for the management of post liver transplant biliary anastomotic strictures. *BMC Gastroenterol* 2020; **20**: 329 [PMID: 33028218 DOI: 10.1186/s12876-020-01479-6]

59 **Wilson C**, Auld CD, Schlinkert R, Hasan AH, Imrie CW, MacSween RN, Carter DC. Hepatobiliary complications in chronic pancreatitis. *Gut* 1989; **30**: 520-527 [PMID: 2714685 DOI: 10.1136/gut.30.4.520]

60 **Mangiavillano B**, Pagano N, Baron TH, Luigiano C. Outcome of stenting in biliary and pancreatic benign and malignant diseases: A comprehensive review. *World J Gastroenterol* 2015; **21**: 9038-9054 [PMID: 26290631 DOI: 10.3748/wjg.v21.i30.9038]

61 **Arslanlar S**, Jain R. Benign biliary strictures related to chronic pancreatitis: balloons, stents, or surgery. *Curr Treat Options Gastroenterol* 2007; **10**: 369-375 [PMID: 17897575 DOI: 10.1007/s11938-007-0037-8]

62 **Hu B**, Sun B, Cai Q, Wong Lau JY, Ma S, Itoi T, Moon JH, Yasuda I, Zhang X, Wang HP, Ryozawa S, Rerknimitr R, Li W, Kutsumi H, Lakhtakia S, Shiomi H, Ji M, Li X, Qian D, Yang Z, Zheng X. Asia-Pacific consensus guidelines for endoscopic management of benign biliary strictures. *Gastrointest Endosc* 2017; **86**: 44-58 [PMID: 28283322 DOI: 10.1016/j.gie.2017.02.031]

63 **Poley JW**, Ponchon T, Puespoek A, Bruno M, Roy A, Peetermans J, Rousseau M, Lépilliez V, Dolak W, Tringali A, Blero D, Carr-Locke D, Costamagna G, Devière J; Benign Biliary Stenoses Working Group. Fully covered self-expanding metal stents for benign biliary stricture after orthotopic liver transplant: 5-year outcomes. *Gastrointest Endosc* 2020; **92**: 1216-1224 [PMID: 32417298 DOI: 10.1016/j.gie.2020.04.078]

64 **Sharaiha RZ**, Novikov A, Weaver K, Marfatia P, Buscaglia JM, DiMaio CJ, Diehl D, Gabr MM, Gaidhane M, Siddiqui A, Kahaleh M. Fully covered self-expanding metal stents for refractory pancreatic duct strictures in symptomatic chronic pancreatitis, US experience. *Endosc Int Open* 2019; **7**: E1419-E1423 [PMID: 31673613 DOI: 10.1055/a-0858-2169]

65 **Moon SH**, Kim MH, Park DH, Song TJ, Eum J, Lee SS, Seo DW, Lee SK. Modified fully covered self-expandable metal stents with antimigration features for benign pancreatic-duct strictures in advanced chronic pancreatitis, with a focus on the safety profile and reducing migration. *Gastrointest Endosc* 2010; **72**: 86-91 [PMID: 20493483 DOI: 10.1016/j.gie.2010.01.063]

66 **Park DH**, Kim MH, Moon SH, Lee SS, Seo DW, Lee SK. Feasibility and safety of placement of a newly designed, fully covered self-expandable metal stent for refractory benign pancreatic ductal strictures: a pilot study (with video). *Gastrointest Endosc* 2008; **68**: 1182-1189 [PMID: 19028228 DOI: 10.1016/j.gie.2008.07.027]

67 **Lakhtakia S**, Reddy N, Dolak W, Ponchon T, Bruno MJ, Bourke MJ, Neuhaus H, Roy A, González-Huix Lladó F, Kortan PP, Peetermans J, Rousseau M, Costamagna G, Devière J; Benign Biliary Stenoses Working Group. Long-term outcomes after temporary placement of a self-expanding fully covered metal stent for benign biliary strictures secondary to chronic pancreatitis. *Gastrointest Endosc* 2020; **91**: 361-369.e3 [PMID: 31494135 DOI: 10.1016/j.gie.2019.08.037]

68 **Kahl S**, Zimmermann S, Genz I, Glasbrenner B, Pross M, Schulz HU, Mc Namara D, Schmidt U, Malfertheiner P. Risk factors for failure of endoscopic stenting of biliary strictures in chronic pancreatitis: a prospective follow-up study. *Am J Gastroenterol* 2003; **98**: 2448-2453 [PMID: 14638347 DOI: 10.1111/j.1572-0241.2003.08667.x]

69 **Smits ME**, Rauws EA, van Gulik TM, Gouma DJ, Tytgat GN, Huibregtse K. Long-term results of endoscopic stenting and surgical drainage for biliary stricture due to chronic pancreatitis. *Br J Surg* 1996; **83**: 764-768 [PMID: 8696734 DOI: 10.1002/bjs.1800830612]

70 **Dorrell R**, Pawa S, Pawa R. Endoscopic Management of Malignant Biliary Stricture. *Diagnostics (Basel)* 2020; **10** [PMID: 32532018 DOI: 10.3390/diagnostics10060390]

71 **Kapoor BS**, Mauri G, Lorenz JM. Management of Biliary Strictures: State-of-the-Art Review. *Radiology* 2018; **289**: 590-603 [PMID: 30351249 DOI: 10.1148/radiol.2018172424]

72 **Goodman MT**, Yamamoto J. Descriptive study of gallbladder, extrahepatic bile duct, and ampullary cancers in the United States, 1997-2002. *Cancer Causes Control* 2007; **18**: 415-422 [PMID: 17264972 DOI: 10.1007/s10552-006-0109-4]

73 **Pinter M**, Hucke F, Zielonke N, Waldhör T, Trauner M, Peck-Radosavljevic M, Sieghart W. Incidence and mortality trends for biliary tract cancers in Austria. *Liver Int* 2014; **34**: 1102-1108 [PMID: 24119058 DOI: 10.1111/liv.12325]

74 **van der Gaag NA**, Rauws EA, van Eijck CH, Bruno MJ, van der Harst E, Kubben FJ, Gerritsen JJ, Greve JW, Gerhards MF, de Hingh IH, Klinkenbijl JH, Nio CY, de Castro SM, Busch OR, van Gulik TM, Bossuyt PM, Gouma DJ. Preoperative biliary drainage for cancer of the head of the pancreas. *N Engl J Med* 2010; **362**: 129-137 [PMID: 20071702 DOI: 10.1056/NEJMoa0903230]

75 **Moole H**, Bechtold M, Puli SR. Efficacy of preoperative biliary drainage in malignant obstructive jaundice: a meta-analysis and systematic review. *World J Surg Oncol* 2016; **14**: 182 [PMID: 27400651 DOI: 10.1186/s12957-016-0933-2]

76 **Sewnath ME**, Karsten TM, Prins MH, Rauws EJ, Obertop H, Gouma DJ. A meta-analysis on the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice. *Ann Surg* 2002; **236**: 17-27 [PMID: 12131081 DOI: 10.1097/00000658-200207000-00005]

77 **Dumonceau JM**, Tringali A, Papanikolaou IS, Blero D, Mangiavillano B, Schmidt A, Vanbiervliet G, Costamagna G, Devière J, García-Cano J, Gyökeres T, Hassan C, Prat F, Siersema PD, van Hooft JE. Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated October 2017. *Endoscopy* 2018; **50**: 910-930 [PMID: 30086596 DOI: 10.1055/a-0659-9864]

78 **ASGE Standards of Practice Committee**, Eloubeidi MA, Decker GA, Chandrasekhara V, Chathadi KV, Early DS, Evans JA, Fanelli RD, Fisher DA, Foley K, Hwang JH, Jue TL, Lightdale JR, Pasha SF, Saltzman JR, Sharaf R, Shergill AK, Cash BD, DeWitt JM. The role of endoscopy in the evaluation and management of patients with solid pancreatic neoplasia. *Gastrointest Endosc* 2016; **83**: 17-28 [PMID: 26706297 DOI: 10.1016/j.gie.2015.09.009]

79 **Fernandez Y Viesca M**, Arvanitakis M. Early Diagnosis And Management Of Malignant Distal Biliary Obstruction: A Review On Current Recommendations And Guidelines. *Clin Exp Gastroenterol* 2019; **12**: 415-432 [PMID: 31807048 DOI: 10.2147/CEG.S195714]

80 **Zorrón Pu L**, de Moura EG, Bernardo WM, Baracat FI, Mendonça EQ, Kondo A, Luz GO, Furuya Júnior CK, Artifon EL. Endoscopic stenting for inoperable malignant biliary obstruction: A systematic review and meta-analysis. *World J Gastroenterol* 2015; **21**: 13374-13385 [PMID: 26715823 DOI: 10.3748/wjg.v21.i47.13374]

81 **Moole H**, Jaeger A, Cashman M, Volmar FH, Dhillon S, Bechtold ML, Puli SR. Are self-expandable metal stents superior to plastic stents in palliating malignant distal biliary strictures? A meta-analysis and systematic review. *Med J Armed Forces India* 2017; **73**: 42-48 [PMID: 28123244 DOI: 10.1016/j.mjafi.2016.08.014]

82 **Yuan TW**, Liu HQ, Wang SB, Cao J. Comparison of plastic stents with self-expandable metal stents in palliative treatment of malignant biliary obstruction: a meta-analysis. *Eur Rev Med Pharmacol Sci* 2017; **21**: 2847-2857 [PMID: 28682432]

83 **Lee JH**, Krishna SG, Singh A, Ladha HS, Slack RS, Ramireddy S, Raju GS, Davila M, Ross WA. Comparison of the utility of covered metal stents versus uncovered metal stents in the management of malignant biliary strictures in 749 patients. *Gastrointest Endosc* 2013; **78**: 312-324 [PMID: 23591331 DOI: 10.1016/j.gie.2013.02.032]

84 **Conio M**, Mangiavillano B, Caruso A, Filiberti RA, Baron TH, De Luca L, Signorelli S, Crespi M, Marini M, Ravelli P, Conigliaro R, De Ceglie A. Covered versus uncovered self-expandable metal stent for palliation of primary malignant extrahepatic biliary strictures: a randomized multicenter study. *Gastrointest Endosc* 2018; **88**: 283-291.e3 [PMID: 29653120 DOI: 10.1016/j.gie.2018.03.029]

85 **Saleem A**, Leggett CL, Murad MH, Baron TH. Meta-analysis of randomized trials comparing the patency of covered and uncovered self-expandable metal stents for palliation of distal malignant bile duct obstruction. *Gastrointest Endosc* 2011; **74**: 321-327.e1-3 [PMID: 21683354 DOI: 10.1016/j.gie.2011.03.1249]

86 **Almadi MA**, Barkun AN, Martel M. No benefit of covered *vs* uncovered self-expandable metal stents in patients with malignant distal biliary obstruction: a meta-analysis. *Clin Gastroenterol Hepatol* 2013; **11**: 27-37.e1 [PMID: 23103324 DOI: 10.1016/j.cgh.2012.10.019]

87 **Jarnagin W**, Winston C. Hilar cholangiocarcinoma: diagnosis and staging. *HPB (Oxford)* 2005; **7**: 244-251 [PMID: 18333200 DOI: 10.1080/13651820500372533]

88 **Bismuth H**, Majno PE. Biliary strictures: classification based on the principles of surgical treatment. *World J Surg* 2001; **25**: 1241-1244 [PMID: 11596882 DOI: 10.1007/s00268-001-0102-8]

89 **Abraham NS**, Barkun JS, Barkun AN. Palliation of malignant biliary obstruction: a prospective trial examining impact on quality of life. *Gastrointest Endosc* 2002; **56**: 835-841 [PMID: 12447294 DOI: 10.1067/mge.2002.129868]

90 **Lee TH**, Moon JH, Park SH. Bilateral metallic stenting in malignant hilar obstruction. *Clin Endosc* 2014; **47**: 440-446 [PMID: 25325005 DOI: 10.5946/ce.2014.47.5.440]

91 **Hong W**, Chen S, Zhu Q, Chen H, Pan J, Huang Q. Bilateral stenting methods for hilar biliary obstructions. *Clinics (Sao Paulo)* 2014; **69**: 647-652 [PMID: 25318098 DOI: 10.6061/clinics/2014(09)12]

92 **De Palma GD**, Galloro G, Siciliano S, Iovino P, Catanzano C. Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study. *Gastrointest Endosc* 2001; **53**: 547-553 [PMID: 11323577 DOI: 10.1067/mge.2001.113381]

93 **Lee TH**, Kim TH, Moon JH, Lee SH, Choi HJ, Hwangbo Y, Hyun JJ, Choi JH, Jeong S, Kim JH, Park DH, Han JH, Park SH. Bilateral *vs* unilateral placement of metal stents for inoperable high-grade malignant hilar biliary strictures: a multicenter, prospective, randomized study (with video). *Gastrointest Endosc* 2017; **86**: 817-827 [PMID: 28479493 DOI: 10.1016/j.gie.2017.04.037]

94 **Aghaie Meybodi M**, Shakoor D, Nanavati J, Ichkhanian Y, Vosoughi K, Brewer Gutierrez OI, Kalloo AN, Singh V, Kumbhari V, Ngamruengphong S, Khashab MA. Unilateral versus bilateral endoscopic stenting in patients with unresectable malignant hilar obstruction: a systematic review and meta-analysis. *Endosc Int Open* 2020; **8**: E281-E290 [PMID: 32118102 DOI: 10.1055/a-1067-4326]

95 **Staub J**, Siddiqui A, Murphy M, Lam R, Parikh M, Pleskow D, Papachristou G, Sharaiha R, Iqbal U, Loren D, Kowalski T, Noor A, Mumtaz T, Yasuda I, Thomas S, Hsaeeb A, Herrick J, Greene T, Adler DG. Unilateral versus bilateral hilar stents for the treatment of cholangiocarcinoma: a multicenter international study. *Ann Gastroenterol* 2020; **33**: 202-209 [PMID: 32127742 DOI: 10.20524/aog.2020.0451]

96 **Chang WH**, Kortan P, Haber GB. Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage. *Gastrointest Endosc* 1998; **47**: 354-362 [PMID: 9609426 DOI: 10.1016/s0016-5107(98)70218-4]

97 **Naitoh I**, Ohara H, Nakazawa T, Ando T, Hayashi K, Okumura F, Okayama Y, Sano H, Kitajima Y, Hirai M, Ban T, Miyabe K, Ueno K, Yamashita H, Joh T. Unilateral versus bilateral endoscopic metal stenting for malignant hilar biliary obstruction. *J Gastroenterol Hepatol* 2009; **24**: 552-557 [PMID: 19220678 DOI: 10.1111/j.1440-1746.2008.05750.x]

98 **Chang G**, Xia FF, Li HF, Niu S, Xu YS. Unilateral versus bilateral stent insertion for malignant hilar biliary obstruction. *Abdom Radiol (NY)* 2017; **42**: 2745-2751 [PMID: 28477177 DOI: 10.1007/s00261-017-1174-8]

99 **Lee JH**, Kang DH, Kim JY, Lee SM, Kim DH, Park CW, Cho HS, Kim GH, Kim TO, Heo J, Song GA, Cho M, Kim S, Kim CW, Lee JW. Endoscopic bilateral metal stent placement for advanced hilar cholangiocarcinoma: a pilot study of a newly designed Y stent. *Gastrointest Endosc* 2007; **66**: 364-369 [PMID: 17643714 DOI: 10.1016/j.gie.2006.12.061]

100 **Connor S**, Garden OJ. Bile duct injury in the era of laparoscopic cholecystectomy. *Br J Surg* 2006; **93**: 158-168 [PMID: 16432812 DOI: 10.1002/bjs.5266]

101 **Pachter HL**, Hofstetter SR. The current status of nonoperative management of adult blunt hepatic injuries. *Am J Surg* 1995; **169**: 442-454 [PMID: 7694987 DOI: 10.1016/s0002-9610(99)80194-9]

102 **Carrillo EH**, Spain DA, Wohltmann CD, Schmieg RE, Boaz PW, Miller FB, Richardson JD. Interventional techniques are useful adjuncts in nonoperative management of hepatic injuries. *J Trauma* 1999; **46**: 619-22; discussion 622-4 [PMID: 10217224 DOI: 10.1097/00005373-199904000-00010]

103 **Kapoor S**, Nundy S. Bile duct leaks from the intrahepatic biliary tree: a review of its etiology, incidence, and management. *HPB Surg* 2012; **2012**: 752932 [PMID: 22645406 DOI: 10.1155/2012/752932]

104 **Nawaz H**, Papachristou GI. Endoscopic treatment for post-cholecystectomy bile leaks: update and recent advances. *Ann Gastroenterol* 2011; **24**: 161-163 [PMID: 24713786]

105 **Kitami M**, Murakami G, Suzuki D, Takase K, Tsuboi M, Saito H, Takahashi S. Heterogeneity of subvesical ducts or the ducts of Luschka: a study using drip-infusion cholangiography-computed tomography in patients and cadaver specimens. *World J Surg* 2005; **29**: 217-223 [PMID: 15650797 DOI: 10.1007/s00268-004-7652-5]

106 **Trondsen E**, Ruud TE, Nilsen BH, Mårvik R, Myrvold HE, Buanes T, Viste A, Jørgensen PF, Jacobsen T, Rosseland AR. Complications during the introduction of laparoscopic cholecystectomy in Norway. A prospective multicentre study in seven hospitals. *Eur J Surg* 1994; **160**: 145-151 [PMID: 8003567]

107 **Barkun AN**, Rezieg M, Mehta SN, Pavone E, Landry S, Barkun JS, Fried GM, Bret P, Cohen A. Postcholecystectomy biliary leaks in the laparoscopic era: risk factors, presentation, and management. McGill Gallstone Treatment Group. *Gastrointest Endosc* 1997; **45**: 277-282 [PMID: 9087834 DOI: 10.1016/s0016-5107(97)70270-0]

108 **Shah JN**. Endoscopic treatment of bile leaks: current standards and recent innovations. *Gastrointest Endosc* 2007; **65**: 1069-1072 [PMID: 17531644 DOI: 10.1016/j.gie.2007.02.022]

109 **Canena J**, Horta D, Coimbra J, Meireles L, Russo P, Marques I, Ricardo L, Rodrigues C, Capela T, Carvalho D, Loureiro R, Dias AM, Ramos G, Coutinho AP, Romão C, Veiga PM. Outcomes of endoscopic management of primary and refractory postcholecystectomy biliary leaks in a multicentre review of 178 patients. *BMC Gastroenterol* 2015; **15**: 105 [PMID: 26285593 DOI: 10.1186/s12876-015-0334-y]

110 **Martins FP**, Phillips M, Gaidhane MR, Schmitt T, Kahaleh M. Biliary leak in post-liver-transplant patients: is there any place for metal stent? *HPB Surg* 2012; **2012**: 684172 [PMID: 22619479 DOI: 10.1155/2012/684172]

111 **Lalezari D**, Singh I, Reicher S, Eysselein VE. Evaluation of fully covered self-expanding metal stents in benign biliary strictures and bile leaks. *World J Gastrointest Endosc* 2013; **5**: 332-339 [PMID: 23858377 DOI: 10.4253/wjge.v5.i7.332]

112 **Kahaleh M**, Sundaram V, Condron SL, De La Rue SA, Hall JD, Tokar J, Friel CM, Foley EF, Adams RB, Yeaton P. Temporary placement of covered self-expandable metallic stents in patients with biliary leak: midterm evaluation of a pilot study. *Gastrointest Endosc* 2007; **66**: 52-59 [PMID: 17324415 DOI: 10.1016/j.gie.2006.07.036]

113 **Li ZH**, Chen M, Liu JK, Ding J, Dong JH. Endoscopic sphincterotomy in the treatment of cholangiopancreatic diseases. *World J Gastroenterol* 2005; **11**: 2678-2680 [PMID: 15849834 DOI: 10.3748/wjg.v11.i17.2678]

114 **Lin WC**, Lin HH, Hung CY, Shih SC, Chu CH. Clinical endoscopic management and outcome of post-endoscopic sphincterotomy bleeding. *PLoS One* 2017; **12**: e0177449 [PMID: 28545082 DOI: 10.1371/journal.pone.0177449]

115 **Ferreira LE**, Baron TH. Post-sphincterotomy bleeding: who, what, when, and how. *Am J Gastroenterol* 2007; **102**: 2850-2858 [PMID: 18042116 DOI: 10.1111/j.1572-0241.2007.01563.x]

116 **Cochrane J**, Schlepp G. Comparing endoscopic intervention against fully covered self-expanding metal stent placement for post-endoscopic sphincterotomy bleed (CEASE Study). *Endosc Int Open* 2016; **4**: E1261-E1264 [PMID: 27995186 DOI: 10.1055/s-0042-118227]

117 **Shah JN**, Marson F, Binmoeller KF. Temporary self-expandable metal stent placement for treatment of post-sphincterotomy bleeding. *Gastrointest Endosc* 2010; **72**: 1274-1278 [PMID: 20951987 DOI: 10.1016/j.gie.2010.08.012]

118 **Itoi T**, Yasuda I, Doi S, Mukai T, Kurihara T, Sofuni A. Endoscopic hemostasis using covered metallic stent placement for uncontrolled post-endoscopic sphincterotomy bleeding. *Endoscopy* 2011; **43**: 369-372 [PMID: 21360425 DOI: 10.1055/s-0030-1256126]

119 **Majmudar K,** Murad F. Fully-Covered Self-Expandable Metal Stents May Increase the Risk of Cholecystitis in Patients With Intact Gallbladders Compared to Uncovered Self-Expandable Metal Stents When Placed for Malignant Biliary Obstruction: 7. *Am J Gastroenterol* 2018; **113** [DOI:10.14309/00000434-201810001-00007]

120 **Haseeb A**, Siddiqui A, Taylor LJ, Mills A, Kowalski TE, Loren DE, Dahmus J, Yalamanchili S, Cao C, Canakis A, Mumtaz T, Parikh M, Adler DG. Use of fully covered self-expanding metal stents for benign biliary etiologies: a large multi-center experience. *Minerva Gastroenterol Dietol* 2018; **64**: 111-116 [PMID: 28875690 DOI: 10.23736/S1121-421X.17.02428-X]

121 **Perri V**, Boškoski I, Tringali A, Familiari P, Mutignani M, Marmo R, Costamagna G. Fully covered self-expandable metal stents in biliary strictures caused by chronic pancreatitis not responding to plastic stenting: a prospective study with 2 years of follow-up. *Gastrointest Endosc* 2012; **75**: 1271-1277 [PMID: 22464813 DOI: 10.1016/j.gie.2012.02.002]

122 **Park DH**, Lee SS, Lee TH, Ryu CH, Kim HJ, Seo DW, Park SH, Lee SK, Kim MH, Kim SJ. Anchoring flap *vs* flared end, fully covered self-expandable metal stents to prevent migration in patients with benign biliary strictures: a multicenter, prospective, comparative pilot study (with videos). *Gastrointest Endosc* 2011; **73**: 64-70 [PMID: 21184871 DOI: 10.1016/j.gie.2010.09.039]

123 **Katsinelos P**, Lazaraki G, Gkagkalis S, Chatzimavroudis G, Anastasiadou K, Georgakis N, Giouleme O, Zavos C, Kountouras J. A fully covered self-expandable metal stent anchored by a 10-Fr double pigtail plastic stent: an effective anti-migration technique. *Ann Gastroenterol* 2017; **30**: 114-117 [PMID: 28042247 DOI: 10.20524/aog.2016.0089]

124 **Kahaleh M**, Talreja JP, Loren DE, Kowalski TE, Poneros JM, Degaetani M, Raijman I, Sejpal DV, Patel S, Rosenkranz L, McNamara KN, Brijbassie A, Wang AY, Gaidhane M, Sethi A, Stevens PD. Evaluation of a fully covered self-expanding metal stent with flared ends in malignant biliary obstruction: a multicenter study. *J Clin Gastroenterol* 2013; **47**: e96-100 [PMID: 23933803 DOI: 10.1097/MCG.0b013e3182951a32]

125 **Paik WH**, Woo SM, Chun JW, Song BJ, Lee WJ, Ahn DW, Lee YS, Choi YH, Ryu JK, Kim YT, Lee SH. Efficacy of an internal anchoring plastic stent to prevent migration of a fully covered metal stent in malignant distal biliary strictures: a randomized controlled study. *Endoscopy* 2021; **53**: 578-585 [PMID: 32886935 DOI: 10.1055/a-1256-0571]

126 **Isayama H**, Komatsu Y, Tsujino T, Sasahira N, Hirano K, Toda N, Nakai Y, Yamamoto N, Tada M, Yoshida H, Shiratori Y, Kawabe T, Omata M. A prospective randomised study of "covered" versus "uncovered" diamond stents for the management of distal malignant biliary obstruction. *Gut* 2004; **53**: 729-734 [PMID: 15082593 DOI: 10.1136/gut.2003.018945]

127 **Jang S**, Stevens T, Parsi M, Lopez R, Zuccaro G, Dumot J, Vargo JJ. Association of covered metallic stents with cholecystitis and stent migration in malignant biliary stricture. *Gastrointest Endosc* 2018; **87**: 1061-1070 [PMID: 28867074 DOI: 10.1016/j.gie.2017.08.024]

128 **Gardner TB**, Spangler CC, Byanova KL, Ripple GH, Rockacy MJ, Levenick JM, Smith KD, Colacchio TA, Barth RJ, Zaki BI, Tsapakos MJ, Gordon SR. Cost-effectiveness and clinical efficacy of biliary stents in patients undergoing neoadjuvant therapy for pancreatic adenocarcinoma in a randomized controlled trial. *Gastrointest Endosc* 2016; **84**: 460-466 [PMID: 26972022 DOI: 10.1016/j.gie.2016.02.047]

129 **Motte S**, Deviere J, Dumonceau JM, Serruys E, Thys JP, Cremer M. Risk factors for septicemia following endoscopic biliary stenting. *Gastroenterology* 1991; **101**: 1374-1381 [PMID: 1936809 DOI: 10.1016/0016-5085(91)90091-x]

**Footnotes**

**Conflict-of-interest statement:** None of the authors have any conflicts of interest to disclose.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding Author's Membership in Professional Societies:** American Gastroenterological Association; American College of Gastroenterology; American Society for Gastrointestinal Endoscopy.

**Peer-review started:** March 30, 2021

**First decision:** June 23, 2021

**Article in press:** August 27, 2021

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Kosuga T **S-Editor:** Ma YJ **L-Editor:** A **P-Editor:** Xing YX

**Figure Legends**

** **

**A B**

** **

**C D**



**E**

**Figure 1 Various types of plastic and metal stents for endoscopic treatment**. A: Plastic biliary stent (10 Fr with flaps); B: Uncovered metal biliary stent; C: Partially covered metal biliary stent; D: Fully covered self-expandable metal biliary stent; E: Fully covered self-expandable metal biliary stent with anti-migration fins (Images B-D courtesy of Boston Scientific Corporation, Boston, United States).

** **

**A B**

** **

**C D**

****

**E**

**Figure 2 Endoscopic retrograde cholangiopancreatography showing cholangiocarcinoma in mid and distal common bile duct compared to normal anatomy.** A: Normal anatomy demomonstrating patent cystic, common bile, and intrahepatic ducts; B: Mid common bile duct biliary stricture with dilated common bile duct and intrahepatic ducts; C: Distalcommon bile duct biliary stricture with dilated common bile duct and intrahepaptic ducts; D: Fully covered self-expandable metal stent (FCSEMS) placement in the common bile duct; E: Endoscopic view of FCSEMS placed in the distal common bile duct.

**** ****

A B

**Figure 3 Endoscopic treatment of biliary leak after donor liver transplantation.** A: Extravasation of contrast at site of biliary leak; B: Resolution of biliary leak after placement of a fully covered self-expandable metal stent.

**Table 1 Strengths and disadvantages of plastic stents and self-expandable metal stents**

|  |  |  |
| --- | --- | --- |
|  | **Strengths** | **Disadvantages** |
| **Plastic stents** | Easy placement, removal, and exchange; Cost-effective for use < 4 mo; Variety of shapes and sizes | Tendency for stent occlusion after several months |
| **Uncovered self-expandable metal stents (USEMS)** | Long stent patency due to large luminal diameter; Stent malposition is rare | Cost-effective for use > 4 mo; High risk for tissue ingrowth or tumor overgrowth; Risk for duodenal wall erosion; Biliary leakage possible; Difficult to reposition or remove |
| **Partially covered self-expandable metal stents (PCSEMS)** | Long stent patency due to large luminal diameter; Biliary leakage is rare | Cost-effective for use > 4 mo; Intermediate risk for tissue ingrowth or tumor overgrowth; Risk for duodenal wall erosion; Difficult to reposition or remove; Side branch obstruction possible |
| **Fully covered self-expandable metal stents (FCSEMS)** | Long stent patency due to large luminal diameter, covering inhibits tissue/tumor in-growth through mesh; No biliary leakage | Cost-effective for use > 4 mo; Risk for duodenal wall erosion; Difficult to reposition or remove; High risk of stent migration; Side branch obstruction possible |

**Table 2 Etiology of benign biliary strictures**

|  |  |
| --- | --- |
| **Extrinsic** | **Intrinsic** |
| Chronic pancreatitis | Post-operative (*i.e.*, post-liver transplantation and post-cholecystectomy) |
| Pancreatic fluid collection | Primary sclerosing cholangitis |
| Cholecystitis | IgG Cholangiopathy |

IgG: Immunoglobin G.

**Table 3 Comparison of study outcomes of plastic stents and fully covered self-expandable metal stents for treatment of post-operative benign biliary strictures**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Methods** | **Patients** | **Stent placement** | **Followup time****(mo)** | **Clinical success1 (%)** | **Recurrence (%)** |
| Bergman *et al*[42] | Retrospective, single center | 57 | Two 10F plastic stents | 24 | 77 | 20 |
| Costamagna *et al*[41] | Retrospective, single center | 154 | Multiple plastic stents | 108 | 96.7 | 12 |
| Chaput *et al*[44] | Retrospective, single center | 92 | FCSEMS | 12 | 84.9 | 21.9 |
| Tringali *et al*[47] | Prospective, mult-center | 187 | FCSEMS | 60 | 83.3 | 15.4 |

1Clinical success defined as removal of stent for resolution of benign biliary stricture. FCSEMS: Fully covered self-expandable metal stents.

**Table 4 Comparison of study outcomes usng fully covered self-expanding metal stents for treatment of biliary leak**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **Methods** | **Patients** | **Type, duration of stent placement (mo)** | **Follow-up time (mo)** | **Clinical success rate1 (%)** |
| Martins *et al*[110] | Restrospective, single center | 31 | PCSEMS (3), FCSEMS with fins (3.3), FCSEMS with flare ends (3) | PCSEMS (44), FCSEMS with fins (27), FCSEMS with flare ends (6.6) | PCSEMS (100), FCSEMS with fins (77.8), FCSEMS with flare ends (70) |
| Lalezari *et al*[111] | Retrospective, single center | 5 | FCSEMS with fins (3) | 26 | 100 |
| Kahaleh *et al*[112] | Retrospective single, center | 16 | FCSEMS (3) | 9 | 94 |

1Clinical success rate defined as resolution of biliary leak confirmed with imaging. PCSEMS: Partially covered self-expandable metal stents; FCSEMS: Fully covered self-expandable metal stents.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**